The online version of this article (doi:10.1186/1475-2840-11-3) contains supplementary material, which is available to authorized users.
All authors are employees of Boehringer Ingelheim, the sponsor of the study.
All authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors. All authors contributed to or participated in the design of the study, the analysis of data, the collection of data, and the writing or revision of the manuscript. All authors reviewed and approved the final version of the manuscript.
This study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin versus comparator treatments.
This was a pre-specified meta-analysis of CV events in linagliptin or comparator-treated patients with type 2 diabetes mellitus (T2DM) from eight Phase 3 studies. All suspected CV events were prospectively adjudicated by a blinded independent expert committee. The primary endpoint was a composite of CV death, stroke, myocardial infarction, and hospitalization for unstable angina. Three secondary composite endpoints derived from the adjudicated CV events were also pre-specified. Risk estimates were calculated using several statistical methods including Cox regression analysis.
Of 5239 treated patients (mean ± SD HbA1c 65 ± 10 mmol/mol [8.0 ± 0.9%], age 58 ± 10 years, BMI 29 ± 5 kg/m2), 3319 received linagliptin once daily (5 mg, 3159; 10 mg, 160) and 1920 received comparators (placebo, 977; glimepiride 1-4 mg, 781; voglibose 0.6 mg, 162). Cumulative exposure (patient-years) was 2060 for linagliptin and 1372 for comparators. Primary CV events occurred in 11 (0.3%) patients receiving linagliptin and 23 (1.2%) receiving comparators. The hazard ratio (HR) for the primary endpoint showed significantly lower risk with linagliptin than comparators (HR 0.34 [95% confidence interval (CI) 0.16-0.70]) as did estimates for all secondary endpoints (HR ranging from 0.34 to 0.55 [all upper 95% CIs < 1.0]).
These results from a large Phase 3 programme support the hypothesis that linagliptin may have CV benefits in patients with T2DM.
Additional file 1: Table S1 Overview of linagliptin Phase 3 clinical trials included in the CV meta-analysis. (PDF 7 KB)12933_2011_430_MOESM1_ESM.PDF
Additional file 2: Figure S1 Subgroup analyses of incidence rates of primary endpoint for linagliptin versus total comparators. (PDF 27 KB)12933_2011_430_MOESM2_ESM.PDF
Additional file 3: Table S2 Risk for other CV endpoints with linagliptin versus total comparators based on various statistical methods. (PDF 7 KB)12933_2011_430_MOESM3_ESM.PDF
Authors’ original file for figure 112933_2011_430_MOESM4_ESM.jpeg
Authors’ original file for figure 212933_2011_430_MOESM5_ESM.jpeg
Authors’ original file for figure 312933_2011_430_MOESM6_ESM.jpeg
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358: 2560-2572. CrossRefPubMed
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009, 360: 129-139. 10.1056/NEJMoa0808431. CrossRefPubMed
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009, 32: 187-192. 10.2337/dc08-9026. PubMedCentralCrossRefPubMed
European Medicines Agency, Committee for Medicinal Products for Human Use: Draft guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. [ http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500073570.pdf]
Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. [ http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf]
Scheen AJ: Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol. 2011, 1561-1576. 7
Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA: Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011, 13: 258-267. 10.1111/j.1463-1326.2010.01350.x. CrossRefPubMed
Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ: Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011, 13: 65-74. 10.1111/j.1463-1326.2010.01326.x. CrossRefPubMed
Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA: Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study. Diabetes Obes Metab. 2011, 13: 653-661. 10.1111/j.1463-1326.2011.01391.x. CrossRefPubMed
United States Renal Data System: Chapter 1. CKD in the General Population. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2009, Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ: Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010, 10: 7-10.1186/1472-6823-10-7. PubMedCentralCrossRefPubMed
Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W: Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010, 12: 485-494. 10.1111/j.1463-1326.2010.01215.x. CrossRefPubMed
Knorr M, Schell R, Steven S, Heeren T, Schuff A, Oelze M, Schuhmacher S, Hausding M, Muenzel T, Klein T, Daiber A: Comparison of direct and indirect antioxidant effects of linagliptin (BI 1356, ONDERO) with other gliptins-evidence for anti-inflammatory properties of linagliptin. Free Radic Biol Med. 2010, 49: S197-(abstract) CrossRef
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
Odd Erik Johansen
Maximilian von Eynatten
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II